Navigation Links
Piedmont Pharmaceuticals Secures $8.5 Million Investment
Date:11/12/2007

GREENSBORO, N.C., Nov. 12 /PRNewswire/ -- Piedmont Pharmaceuticals LLC, a specialty pharmaceutical company focused on parasitology and drug delivery systems for human and companion animal use, has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other accredited investors.

This funding will help advance development of Piedmont Pharmaceuticals' pipeline, particularly the U.S. Phase III clinical trials of its unique patented, insecticide-free head lice treatment. Through licensees abroad, this pediculicide rinse is already approved and is the market leader in the United Kingdom and Ireland (under the name Full Marks Solution(R)) and gaining market share in Canada (as RESULTZ(R)). While no timetable has been set, Piedmont Pharmaceuticals anticipates expanding distribution of the product through licensees in the European, Asian and Australasian markets.

"We are very pleased to be working with an investment company of CM Capital's geographical scope and expertise," said Roland Johnson, CEO and Chairman of the Board for Piedmont Pharmaceuticals. "We believe this investment, the first major institutional backing for Piedmont Pharmaceuticals, sends a strong signal about our company's progress and potential. As we move our pediculicide compound through Phase III trials and continue developing the rest of our portfolio, we welcome the guidance and global connections that CM Capital can offer."

"CM Capital invests in companies that can achieve market leadership positions in their respective market sectors," said Andy Jane, partner at CM Capital Investments. "With its talented and proven team of industry veterans, Piedmont Pharmaceuticals has an excellent opportunity to succeed in both the human and animal health markets in the U.S. and beyond."

Members of Piedmont Pharmaceuticals' team have worked together in the health care industry for more than 20 years, bringing more than 11 products to market
'/>"/>

SOURCE Piedmont Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... experts advise , , SATURDAY, Dec. 5 (HealthDay News) -- ... can have bad reactions to certain holiday traditions and ... wheezing, according to the American College of Allergy, Asthma ... live evergreens may choose to decorate with artificial plants, ...
(Date:12/5/2009)... their cleaning processes. The technology available to the lab allows it ... customers relating to cleaning parts, process development, and verification. , ... ... a Jackson, MI-based company, is home to an advanced technology center ...
(Date:12/5/2009)... is a collaborative effort by the National Association ... North America (MANA), Citizens for Midwifery (CfM), International ... of Midwives (NARM), and the Midwifery Education Accreditation ... efforts of The MAMA Campaign to secure federal ...
(Date:12/4/2009)... Dec. 4 Varian Medical Systems (NYSE: VAR ... the regular 2010 Annual Meeting of Stockholders for February 11, ... meeting will be held at the Crowne Plaza Cabana Hotel, ... PT. ,, The meeting will be webcast by Thomson Financial ...
(Date:12/4/2009)... 4 Thousands of KPMG LLP employees came together in ... community service event which combines the audit, tax and advisory ... national service day reflects our firm,s long history of volunteerism. ... of caring to brighten the holidays for some children," said ...
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2
... characteristics help fine-tune treatment, study says , , FRIDAY, Dec. ... predicting breast cancer risk, recurrence risk and response to ... density and tumor size, a panel of experts report. ... Friday at the annual San Antonio Breast Cancer Symposium ...
... [The Washington Post Friday reported that the ... the White House are considering easing the official advisory cautioning ... at the Environmental Protection Agency reportedly are concerned about the ... of several "midnight" rules and policy changes in the pipeline ...
... Dec. 12 Roberta Kalafut, D.O., just announced her resignation ... a close the worst abuses of power by the TMB ... disciplinary actions, particularly against her competitors, and stonewalling by the ... "We applaud Kalafut,s resignation," said AAPS Executive Director ...
... climes becoming more conducive to spread , , FRIDAY, Dec. ... risk for infection with so-called "airport malaria" in malaria-free ... , Here,s how it happens, as the scientists explain ... tropical regions, and at the end of a flight ...
... to consumer-directed plan , , ... to make the most of their money, particularly their health ... 2.0, which helps members manage costs and still keep the ... a high-deductible plan with a health savings account (HSA). This ...
... , SAN ANTONIO, TEXAS - Early-stage breast cancer patients ... significant risk of recurrence of their disease, compared to those ... according to a study led by researchers at The University ... presented today at the CRTC-AACR San Antonio Breast Cancer Symposium, ...
Other Medicine News:Health News:Progress Made in Predicting Breast Cancer Risk 2Health News:Progress Made in Predicting Breast Cancer Risk 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:'Airport Malaria' Risk Rising With Global Warming 2Health News:'Airport Malaria' Risk Rising With Global Warming 3Health News:Regence Unveils New Approach to Healthcare With Launch of HSA Healthplan 2.0 2Health News:Early stage, HER2-positive breast cancer patients at increased risk of recurrence 2Health News:Early stage, HER2-positive breast cancer patients at increased risk of recurrence 3
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, ... President and Chief Financial Officer. In this role, ... administrative functions including finance, accounting, IT, IR, administration and ... Company,s senior management team. ,, "One of my ...
(Date:12/4/2009)... Shore and E. David Crawford presented results for prostate-specific ... end points of biochemical recurrence rate in a Phase ... or monthly leuprolide in prostate cancer patients during the ... received FIRMAGON 240/80 mg/month had a recurrence rate of ...
(Date:12/3/2009)... ACTON, Mass., Dec. 3 Allen Medical Systems, a ... ), today announced the launch of its new Allen ... www.AllenAmatech.com . ,, The website reinforces the ... of the new product catalog, with detailed descriptions and ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2EHE International Supports the National Headache Foundation 48180 1EHE International Supports the National Headache Foundation 48180 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 1Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 2Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 3
... Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to ... (Nasdaq and MTA: CTIC) announced today that it achieved the ... pixantrone,(BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based ...
... Demonstrate Test,s Potential for ... Rapid Uptake, ... Applied Biosystems Inc. (NYSE: ABI ) today,announced the launch of BCtect(TM), ... a unique gene expression signature,identified by DiaGenic using a custom TaqMan(R) Array ...
Other Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3